GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Halozyme Therapeutics
Halozyme Therapeutics owns a unique drug delivery technology, ENHANZE, which converts intravenous medications into subcutaneous delivery. Its share price reflects royalties from its partners (major pharmaceutical companies) and the growing application of its technology in oncology.
Share prices of companies in the market segment - Cancer cure
Halozyme Therapeutics operates in a unique biotech segment, developing a platform for subcutaneous drug delivery. We classify it as part of the Cancer Treatment sector, as its technology is widely used in oncology. The chart below shows the dynamics of this innovative segment.
Broad Market Index - GURU.Markets
Halozyme Therapeutics is a biotech company that developed the ENHANZE drug delivery technology, which converts intravenous medications into subcutaneous formulations. Its platform earns it a spot in the GURU.Markets index. The chart below compares its performance with the market.
Change in the price of a company, segment, and market as a whole per day
HALO - Daily change in the company's share price Halozyme Therapeutics
The daily price change for Halozyme, whose technology improves drug delivery, is a measure of its response to the success of its partner drugs. The graph of these fluctuations is unspectacular, but it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer cure
Halozyme Therapeutics, Inc. is a biotech company with a unique drug delivery platform. This chart highlights the sector's high volatility. Comparing it to HALO's performance helps assess how its business model, based on royalties from pharma giants, enhances its stability.
Daily change in the price of a broad market stock, index - GURU.Markets
Halozyme Therapeutics has developed a unique drug delivery technology that converts intravenous medications into subcutaneous forms. Its business model is based on partnerships with major pharmaceutical companies. The chart below illustrates the volatility of the biotech sector, which is interesting to compare with Halozyme's unique story.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Halozyme Therapeutics
Halozyme has developed a unique technology that converts intravenous medications into a subcutaneous form. Its year-over-year growth reflects the success of its partnerships with major pharmaceutical companies, which license this technology for their blockbusters.
Annual dynamics of market capitalization of the market segment - Cancer cure
Halozyme Therapeutics, Inc. possesses a unique technology that converts intravenous medications into a subcutaneous form, making them much more convenient for patients. Its business model is based on partnerships with major pharmaceutical companies. The chart below shows how its revolutionary technology is driving accelerated growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Halozyme Therapeutics, with its ENHANZE technology platform, has a unique business model that depends on the success of its partner drugs. Its performance is weakly correlated with the market, driven by the clinical and commercial success of large pharmaceutical companies using its technology. This is a bet on medical innovation, not economic growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Halozyme Therapeutics
Halozyme Therapeutics owns technology that converts intravenous injections into subcutaneous ones. The monthly fluctuations on the chart reflect the royalties it receives from pharmaceutical giants for using this technology in their blockbusters, providing it with growing cash flow.
Monthly dynamics of market capitalization of the market segment - Cancer cure
This chart reflects the dynamics of the biotech sector. For Halozyme, with its unique drug delivery technology, it's the backdrop. Its movements illustrate how partnerships with major pharmaceutical companies using its technology provide it with a steady stream of royalties.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Halozyme Therapeutics owns a technology that improves drug delivery. Its business model relies on royalties from partners, creating a predictable cash flow. This allows the company's stock to move independently of the broader market, responding to the success of its partners' drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Halozyme Therapeutics
Halozyme Therapeutics owns technology that improves drug delivery. Weekly stock performance is driven by news of partnerships with major pharmaceutical companies and the success of drugs using its technology, creating volatility driven by R&D news.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Halozyme is a biotech company with a unique drug delivery technology. Comparing its weekly performance with the biotech sector reveals the strength of its business model. The chart shows how royalties from partners using its technology provide stability, distinguishing it from riskier R&D companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Halozyme, a biotech company, live in a world of their own. Their performance is driven by news of partnerships and approvals. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
HALO - Market capitalization of the company Halozyme Therapeutics
Halozyme Therapeutics' market capitalization chart tells the story of how one technology can change the way drugs are administered. The company's ENHANZE platform enables the conversion of intravenous medications to subcutaneous injections. Its growth reflects the success of its partnerships with major pharmaceutical companies and the royalty stream generated by this innovation.
HALO - Share of the company's market capitalization Halozyme Therapeutics within the market segment - Cancer cure
Halozyme Therapeutics has developed a unique drug delivery technology that converts intravenous medications into subcutaneous forms. Its market share reflects the value of this platform, which is licensed to major pharmaceutical companies. The chart below shows the importance of this biotech company, which is transforming drug delivery.
Market capitalization of the market segment - Cancer cure
Halozyme Therapeutics has developed a unique drug delivery technology that enables the conversion of intravenous medications to subcutaneous injections. The graph below shows the overall market capitalization of the oncology sector. It illustrates how Halozyme's innovations enhance convenience for patients and value for its pharmaceutical partners.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows how a single technology can improve the performance of dozens of drugs. Halozyme Therapeutics has developed an enzyme that converts intravenous medications into subcutaneous injections. Its market capitalization is the value of this convenience for patients and healthcare systems. The chart demonstrates the power of platform technologies in pharmaceuticals.
Book value capitalization of the company, segment and market as a whole
HALO - Book value capitalization of the company Halozyme Therapeutics
Halozyme's capital is derived from its ENHANZE enzyme technology, which converts intravenous drugs into subcutaneous forms, and its financial reserves. Its book value reflects this unique intellectual asset. The chart shows how licensing deals with pharmaceutical giants using its technology have built and grown the company's capital.
HALO - Share of the company's book capitalization Halozyme Therapeutics within the market segment - Cancer cure
Halozyme Therapeutics doesn't create drugs, but rather develops technology that improves their delivery to the body. Its physical assets (laboratories) are modest. The chart shows that the company's value lies not in its production capacity, but in its patented enzyme platform, which is licensed by pharmaceutical giants.
Market segment balance sheet capitalization - Cancer cure
Halozyme Therapeutics has a unique, lightweight business model. The company doesn't sell drugs, but licenses its ENHANZE drug delivery technology. A BCap_Seg chart for the biotech sector, full of R&D companies, shows that Halozyme's model is even more lightweight and profitable.
Book value of all companies included in the broad market index - GURU.Markets
Halozyme Therapeutics's capital lies not in its factories, but in its unique, patented drug delivery technology, ENHANZE, which converts intravenous medications into subcutaneous injections. Its main asset is its intellectual property. The chart below shows how this intangible yet valuable asset compares to traditional pharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Halozyme Therapeutics
Halozyme's balance sheet isn't its factories, but its revolutionary ENHANZE technology, which converts intravenous medications into subcutaneous ones. The enormous premium reflects the valuation of this platform, which is licensed by the world's largest pharmaceutical companies. The graph represents the value of intellectual property that is transforming medicine.
Market to book capitalization ratio in a market segment - Cancer cure
Halozyme Therapeutics owns a technology that converts intravenous medications into a subcutaneous form. Its value comes from licensing fees from major pharmaceutical companies. The chart demonstrates the high valuation of this unique and profitable business model, based on intellectual property.
Market to book capitalization ratio for the market as a whole
Halozyme Therapeutics owns technology that converts intravenous medications into subcutaneous forms. The company's primary asset is intellectual property, licensed to major pharmaceutical companies. This results in a very high market valuation with a minimal book value, as reflected in this chart.
Debts of the company, segment and market as a whole
HALO - Company debts Halozyme Therapeutics
Halozyme Therapeutics, a biotech company with a unique drug delivery technology, uses its financial position to reward shareholders and investors. Debt can be a tool for capital optimization. This chart shows how a company with stable royalties manages its balance sheet, turning scientific breakthroughs into financial success.
Market segment debts - Cancer cure
Halozyme Therapeutics owns technology that converts intravenous medications into subcutaneous forms, which is highly valuable to pharmaceutical giants. Its business model is based on licensing fees. Its debt policy may be aimed at returning capital to shareholders. This chart shows how the company manages its finances while earning royalties.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Halozyme Therapeutics
Halozyme Therapeutics develops drug delivery technology that converts intravenous medications into subcutaneous injections. This chart shows the company's capital structure. Low debt may indicate that its business, based on royalties from partners, is highly profitable and does not require significant external borrowing.
Market segment debt to market segment book capitalization - Cancer cure
Halozyme Therapeutics owns technology that converts intravenous medications into subcutaneous forms, which is highly valuable for pharmaceutical companies. The business is based on royalties and R&D. The chart shows how this innovative company's debt position compares to the overall market capitalization of the biotech sector.
Debt to book value of all companies in the market
Halozyme Therapeutics, a biotech company with a valuable technology platform, compares its conservative debt policy to the overall market capitalization. This clearly demonstrates the financial profile of this innovative, yet already profitable, company against the backdrop of the broader economy.
P/E of the company, segment and market as a whole
P/E - Halozyme Therapeutics
Halozyme Therapeutics has developed a unique drug delivery technology (ENHANZE), which enables the conversion of intravenous medications into a subcutaneous form. This chart shows how the market is valuing its licensing model. High values reflect successful partnerships with major pharmaceutical companies and growing royalties from sales of drugs using Halozyme's technology.
P/E of the market segment - Cancer cure
Halozyme Therapeutics has a unique business model based on licensing its drug delivery technology. This chart shows the average valuation for the biotech sector. It helps understand the premium the market places on this high-margin, capital-efficient model, which relies on royalties from partners.
P/E of the market as a whole
Halozyme Therapeutics has developed a unique drug delivery technology (ENHANZE), which enables the conversion of intravenous medications into subcutaneous delivery. This chart reflects the overall sentiment in biotech. Halozyme's valuation depends not on its own developments, but on the success of its partners' drugs (Roche, Pfizer), which use its technology, creating a royalty-based business model.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Halozyme Therapeutics
Halozyme Therapeutics owns the ENHANZE drug delivery technology, which converts intravenous medications into subcutaneous formulations. This chart illustrates market expectations for licensing fees and royalties from major pharmaceutical partners. The trendline represents an estimate of the growth in the use of this technology.
%20P%2FE%20Halozyme%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Halozyme-Therapeutics&v=1772656048899 "Chart of the company's future (projected) P/E Halozyme Therapeutics")
Future (projected) P/E of the market segment - Cancer cure
Halozyme Therapeutics owns the ENHANZE drug delivery technology, which converts intravenous medications into subcutaneous formulations. This chart reflects profitability expectations for the sector. It helps understand how highly the market values the company's licensing business model and the potential of its technology to improve existing treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772656048927 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Halozyme Therapeutics is a biotech company that developed the ENHANZE drug delivery technology, which converts intravenous medications into subcutaneous formulations. This chart demonstrates investor appetite for innovation. For a company whose technology is licensed by major pharmaceutical companies, it reflects how the market views its unique business model.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772656048944 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Halozyme Therapeutics
Halozyme Therapeutics is a biotech company with a unique technology, ENHANZE, which converts intravenous medications into a subcutaneous form. The revenue visualized here is generated through royalties from partners—large pharmaceutical companies using this technology. The graph illustrates how a single innovative platform can generate a stable revenue stream.
Profit of companies in the market segment - Cancer cure
Halozyme Therapeutics is a biotech company whose ENHANZE technology converts intravenous medications into a subcutaneous form, making them significantly more convenient for patients. The company licenses its technology to major pharmaceutical companies. This chart illustrates how innovative drug delivery platforms can generate significant licensing revenue and change the standard of care.
Overall market profit
Halozyme Therapeutics develops drug delivery technology that converts intravenous medications into subcutaneous forms. Its revenue comes from royalties from its partners—large pharmaceutical companies. Halozyme's growth reflects the success of its partners' products and exemplifies an innovative business model in the pharmaceutical industry, contributing to the overall picture shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Halozyme Therapeutics
Halozyme Therapeutics is a biotech company with the ENHANZE platform, which converts intravenous medications into subcutaneous forms. The profit projection in this chart depends on the royalties the company receives from pharmaceutical giants for the use of its technology. This is a bet that subcutaneous injections will become the standard for many drugs.
%20profit%20of%20the%20company%20Halozyme%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Halozyme-Therapeutics&v=1772656049061 "Graph of future (projected) profit of the company Halozyme Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer cure
Halozyme Therapeutics is developing a drug delivery technology (ENHANZE) that converts intravenous medications into a subcutaneous form, making them more convenient for patients. The company receives royalties from partners. This graph shows the revenue forecast for the cancer treatment sector, allowing one to assess how Halozyme's unique technology platform creates value in the pharmaceutical industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772656049086 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Halozyme Therapeutics develops technologies that improve drug delivery, specifically converting intravenous medications into subcutaneous forms. Its revenue comes primarily from royalties from partners. This graph, reflecting the state of the pharmaceutical industry, influences the development and commercialization of new drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772656049118 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Halozyme Therapeutics
Halozyme Therapeutics has developed a unique drug delivery technology that converts intravenous medications into subcutaneous forms. This chart shows how investors value its revenue, which consists of royalties from pharmaceutical giants. The high valuation reflects the value and widespread applicability of its technology.
P/S market segment - Cancer cure
Halozyme Therapeutics is a biotech company whose ENHANZE technology converts intravenous medications into a subcutaneous form, making them significantly more convenient for patients. The company's revenue comes from royalties from partners using its technology. This chart helps understand how investors value Halozyme's unique and in-demand platform.
P/S of the market as a whole
Halozyme Therapeutics is a biotech company whose ENHANZE technology converts intravenous medications into a subcutaneous form, making it more convenient for patients. The company receives royalties from partners who use its technology. This chart shows how the market values unique biotech business models based on licensing and partnerships.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Halozyme Therapeutics
Halozyme Therapeutics is developing a technology that enables subcutaneous drug delivery rather than intravenous delivery. This chart shows how the market values the company relative to its future royalty revenue. It reflects investor expectations regarding the implementation of its technology by pharmaceutical partners in their own products.
%20P%2FS%20Halozyme%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Halozyme-Therapeutics&v=1772656049421 "The graph of the company's future (projected) P/S Halozyme Therapeutics")
Future (projected) P/S of the market segment - Cancer cure
Halozyme Therapeutics has developed a unique enzymatic drug delivery technology (ENHANZE), which enables the conversion of intravenous medications into a subcutaneous form. The company receives royalties from partners using its technology. This chart reflects how the market values future revenue from its platform and partnerships.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772656049442 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Halozyme Therapeutics owns a technology that converts intravenous medications into a subcutaneous form, making it more convenient for patients. Its revenue comes from royalties from partners using this technology. This schedule is not a direct driver for HALO. The company's growth depends on the success of its partners' drugs and the conclusion of new licensing agreements.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772656049483 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Halozyme Therapeutics
This chart illustrates the success of this innovative drug delivery technology. For Halozyme Therapeutics, it reflects growing royalties and milestone payments from major pharmaceutical companies. The partners use ENHANZE® technology to convert intravenous medications into subcutaneous injections, generating cash flow.
Sales of companies in the market segment - Cancer cure
Halozyme Therapeutics is developing a drug delivery technology (ENHANZE) that converts intravenous medications into subcutaneous forms. Its revenues primarily come from royalties from pharmaceutical partners. This chart illustrates how the implementation of this technology in blockbuster drugs is impacting Halozyme's cash flow and changing its treatment approaches.
Overall market sales
Halozyme Therapeutics owns a technology that converts intravenous drug delivery into subcutaneous delivery. The company licenses this technology to major pharmaceutical companies, receiving royalties. Its revenue is growing as more and more blockbuster drugs use its platform, reflecting the trend toward patient-friendly medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Halozyme Therapeutics
Halozyme Therapeutics has developed a unique drug delivery technology, ENHANZE, which enables the conversion of intravenous medications into a subcutaneous form. The company's future revenue depends on licensing agreements with major pharmaceutical companies. This graph reflects expectations for the implementation of this innovative technology in oncology and other areas.
%20sales%20of%20the%20company%20Halozyme%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Halozyme-Therapeutics&v=1772656049662 "Schedule of future (projected) sales of the company Halozyme Therapeutics")
Future (projected) sales of companies in the market segment - Cancer cure
Halozyme Therapeutics is developing a drug delivery technology that converts intravenous medications into subcutaneous forms. The forecast for the oncology sector and other therapeutic areas demonstrates the demand for innovation. The chart illustrates the interest of pharmaceutical giants in licensing Halozyme's technology to improve their products.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772656049736 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Halozyme Therapeutics owns a technology that improves drug delivery, which it licenses to major pharmaceutical companies. The company's revenue comes from royalties on sales of its partner companies' drugs. This overall economic activity indirectly impacts Halozyme through the overall health care system and sales of drugs using its technology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772656049762 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Halozyme Therapeutics
Halozyme Therapeutics, a biotech company, shows the profitability of its ENHANZE drug delivery technology in this chart. Profitability is based on royalties from major pharmaceutical partners who use Halozyme's technology to convert intravenous medications into subcutaneous injections, which is significantly more convenient for patients.
Market segment marginality - Cancer cure
Halozyme Therapeutics developed the ENHANZE drug delivery technology, which converts intravenous medications into subcutaneous formulations. This graph shows the average profitability in the biotech sector. Its business model, based on licensing the technology to large pharmaceutical companies, ensures a stable royalty stream and exceptionally high profitability.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Halozyme Therapeutics
Halozyme Therapeutics owns the ENHANZE technology platform, which converts intravenous medications into subcutaneous formulations. Its small but highly effective team manages licensing agreements with major pharmaceutical companies. The growth seen in this graph is due to the success of its partner drugs and the expansion of its technology.
Share of the company's employees Halozyme Therapeutics within the market segment - Cancer cure
Halozyme Therapeutics has developed a unique enzymatic drug delivery technology (ENHANZE), which it licenses to major pharmaceutical companies to enable the conversion of intravenous medications to subcutaneous delivery. This chart demonstrates its scientific prowess, reflecting the percentage of scientists working on this breakthrough technology that Halozyme is attracting.
Number of employees in the market segment - Cancer cure
Halozyme Therapeutics has developed an enzymatic drug delivery technology, ENHANZE, which converts intravenous medications into subcutaneous forms. This graph illustrates how one innovation can transform an entire industry. The technology's success creates a demand for scientists and business development specialists to partner with pharmaceutical giants.
Number of employees in the market as a whole
Halozyme Therapeutics develops technologies that improve drug delivery, specifically by enabling subcutaneous administration instead of intravenous administration. The company's revenue comes from royalties from partners. Overall economic growth, reflected in the graph, supports R&D funding in the pharmaceutical industry, expanding Halozyme's pool of potential partners.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Halozyme Therapeutics (HALO)
Halozyme Therapeutics has developed a unique technology that converts intravenous drugs into a subcutaneous form. This chart demonstrates how a single brilliant idea can generate enormous value. The sky-high market capitalization per employee demonstrates that a small team of scientists has created a platform that is being licensed by all the Big Pharma giants.
%20of%20the%20company%20Halozyme%20Therapeutics%20(HALO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Halozyme-Therapeutics-HALO&v=1772656050010 "Chart of market capitalization per employee (in thousands of dollars) of the company Halozyme Therapeutics (HALO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Halozyme Therapeutics is a biotech company that owns the ENHANZE technology, which converts intravenous drug delivery (for example, for cancer) into a subcutaneous form. They license this technology. This chart shows the industry average cost per employee. It helps assess how much the market values their unique platform technology and royalty stream based on their small R&D staff.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772656050044 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Halozyme Therapeutics is a biotech company that owns the ENHANZE drug delivery technology, which converts intravenous medications into subcutaneous formulations. This graph reflects a very high employee valuation, as the company licenses its platform technology to numerous pharmaceutical giants, earning royalties on their multibillion-dollar sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772656050081 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Halozyme Therapeutics (HALO)
Halozyme Therapeutics is a biotech company with a unique technology (ENHANZE) that allows for the delivery of drugs (for example, for cancer) via a simple subcutaneous injection instead of a lengthy intravenous drip. They license this technology. This figure is extremely high, reflecting how a small team of scientists generates enormous royalties (profits) from the pharma giants using their platform.
%20Chart%20Halozyme%20Therapeutics%20(HALO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Halozyme-Therapeutics-HALO&v=1772656050089 "Company Profit Per Employee (in thousands of dollars) Chart Halozyme Therapeutics (HALO)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Halozyme (HALO) is an R&D platform (ENHANZE) that enables the transfer of "injections" from a vein to the skin. This graph shows the benchmark for "Cancer Treatment" (IP). The average profit per employee here is astronomical. This is a "pure" R&D business. A tiny staff of elite engineers licenses the IP (technology) to pharma giants.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772656050133 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Halozyme Therapeutics has developed a unique drug delivery technology, ENHANZE, which converts intravenous medications into subcutaneous forms. The company licenses this technology to pharmaceutical industry giants. This chart illustrates the IP licensing model: huge royalties with minimal staffing provide one of the highest profits per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772656050144 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Halozyme Therapeutics (HALO)
Halozyme Therapeutics owns a technology that improves drug delivery. This chart demonstrates the effectiveness of its licensing model. The majority of its revenue comes from royalties received from partners using its technology. This allows it to generate high revenue with a very small staff, clearly demonstrating the strength of its intellectual property.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Halozyme-Therapeutics-HALO&v=1772656050236 "Sales chart per company employee Halozyme Therapeutics (HALO)")
Sales per employee in the market segment - Cancer cure
Halozyme Therapeutics is a biotech company that owns a unique drug delivery technology (ENHANZE), which it licenses to major pharmaceutical companies. Their primary income comes from royalties. This graph shows how efficiently their small team of scientists and managers generates high-margin revenue, making their business model unique.
Sales per employee for the market as a whole
Halozyme Therapeutics is a biotech company with a unique drug delivery technology (ENHANZE). It converts intravenous drugs into a simple subcutaneous injection. This graph shows how much revenue each employee generates. High numbers reflect the efficiency of their IP model: they license the technology to large pharma companies and earn royalties without having a large staff.
Short shares by company, segment and market as a whole
Shares shorted by company Halozyme Therapeutics (HALO)
Halozyme Therapeutics owns a technology (ENHANZE) that converts intravenous drug delivery (primarily for cancer) to subcutaneous delivery. The company receives royalties from pharma giants. This chart shows bearish bets. Bears may be concerned that key patents on the technology will soon expire or that new partner drugs will not be approved.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Halozyme-Therapeutics-HALO&v=1772656050420 "Short Shares Chart for the Company Halozyme Therapeutics (HALO)")
Shares shorted by market segment - Cancer cure
Halozyme Therapeutics owns technology (ENHANZE) that converts intravenous medications into subcutaneous injections. They receive royalties from pharma giants. This chart shows the overall short positions in the biotech sector. The high short interest in the industry reflects general investor skepticism about the sector, concerns about patent disputes, and regulatory pressure.
Shares shorted by the overall market
Halozyme is a unique biotech platform. They don't create drugs, but own a technology (ENHANZE) that allows for the administration of drugs (for example, for cancer) subcutaneously, rather than through an IV. Their income comes from royalties. This chart shows the bets against their partners. "Bears" short HALO if they expect the failure of key partner drugs or patent expiration.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Halozyme Therapeutics (HALO)
Halozyme Therapeutics owns a drug delivery technology (ENHANZE), receiving royalties from pharmaceutical giants. The business depends on the success of its partners. A HALO chart above 70 may reflect new partnerships or the success of ENHANZE-based drugs. A level below 30 is associated with concerns about competition or partner failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Halozyme-Therapeutics-HALO&v=1772656050695 "RSI 14 indicator chart for the company's stock Halozyme Therapeutics (HALO)")
RSI 14 Market Segment - Cancer cure
Halozyme Therapeutics (HALO) is a biotech company whose ENHANZE technology allows for the conversion of intravenous (IV) injections (e.g., cancer drugs) to subcutaneous (SC) delivery. The RSI_14_Seg for "Cancer Cure" (biotech) reflects the overall sentiment. It helps us understand whether HALO's growth is due to licensing success or general sector overheating.
RSI 14 for the overall market
Halozyme Therapeutics is a biotech company that owns a unique technology (ENHANZE) that converts intravenous drug delivery to subcutaneous delivery. They license this technology to pharmaceutical giants. This market sentiment chart shows risk appetite. Although Halozyme receives stable royalties, market euphoria helps investors assess the future potential of their platform.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HALO (Halozyme Therapeutics)
Halozyme is a biotech company with a unique technology called ENHANZE. This enzyme converts intravenous injections (such as cancer drugs) into subcutaneous injections. This chart shows the average 12-month target from analysts. It reflects their royalty expectations from pharmaceutical partners (J&J, Roche) using this technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HALO-Halozyme-Therapeutics&v=1772656050913 "A chart showing analyst consensus forecasts for the expected stock price. HALO (Halozyme Therapeutics)")
The difference between the consensus estimate and the actual stock price HALO (Halozyme Therapeutics)
Halozyme Therapeutics owns a technology (ENHANZE) that converts intravenous drug administration to subcutaneous delivery. This chart shows the difference between the market valuation and analyst consensus estimates. It also shows the potential experts see in royalties from their partners (major pharmaceutical companies) using this technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HALO-Halozyme-Therapeutics&v=1772656050986 "A chart showing the difference between the consensus forecast and the actual stock price. HALO (Halozyme Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Halozyme Therapeutics isn't an oncology company, but rather the owner of a technology (ENHANZE) that converts intravenous medications into subcutaneous injections. Pharma giants pay it royalties. This chart shows general expectations for the sector, reflecting whether experts believe this technology has value for the entire pharmaceutical industry.
Analysts' consensus forecast for the overall market share price
Halozyme Therapeutics isn't an oncology company, but rather the owner of a technology (ENHANZE) that allows drugs to be converted from IV drips to subcutaneous injections. Market expectations, as seen in this chart, have little impact on them. Their business is based on royalties from Big Pharma, which doesn't care about economic cycles.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Halozyme Therapeutics
Halozyme Therapeutics is a biotech company with a unique platform called ENHANZE. This enzyme converts intravenous (IV) medications into a simple subcutaneous injection. This graph is an assessment of their technology. They don't sell drugs, but receive royalties from giants (J&J, Roche) for the use of their platform. The graph reflects the success of their partners.
AKIMA Market Segment Index - Cancer cure
Halozyme is a biotech platform that doesn't create drugs, but improves them. Its technology (ENHANZE) converts drugs administered via intravenous drip (IV) into a simple subcutaneous injection (SC). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does Halozyme's unique R&D model (selling its technology) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Halozyme is a biotech platform. Its technology (ENHANZE) allows pharma giants to transform their intravenous medications into simple subcutaneous injections. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this royalty-based platform story stacks up against the broader economic trends affecting markets.
